TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19366489

Group type: EXPERIMENTAL
Intervention: Aripiprazole (partial agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antagonist antipsychotics (risperidone or olanzapine)
Number of subjects: 0
Study: 16955110

Group type: EXPERIMENTAL
Intervention: Cefotaxime/heparin lock (group I)
Number of subjects: 109
Study: 14758576

Group type: EXPERIMENTAL
Intervention: Older bipolar subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Late-onset bipolar subjects
Number of subjects: 36
Study: 11211363

Group type: EXPERIMENTAL
Intervention: MTA behavioral and medication treatments
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: MTA medication treatments (with or without behavioral treatments)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Combined (medication and behavioral) treatments
Number of subjects: 579
Study: 9250633

Group type: EXPERIMENTAL
Intervention: Biphasic transthoracic defibrillation (115 J)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biphasic transthoracic defibrillation (130 J)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monophasic damped-sine wave shock (200 J)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Internal shock
Number of subjects: 30
Study: 7945622

Group type: EXPERIMENTAL
Intervention: Cytokine response to systemic infection (TNF-alpha, IL-1 alpha, IL-1 beta, IL-6)
Number of subjects: 0
Study: 2899236

Group type: EXPERIMENTAL
Intervention: 500 mg acetylsalicylic acid (ASA) orally starting 12 h after admission and then intermittently every third day for one month
Number of subjects: 20

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 mg acetylsalicylic acid (ASA)
Number of subjects: 20
Study: 31569180

Group type: EXPERIMENTAL
Intervention: Psychoeducational pain management intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 42
Study: 30922297

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg orally once daily for 6 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 28610601

Group type: EXPERIMENTAL
Intervention: Face-down positioning for at least 8 hours a day for 5 days post-surgery
Number of subjects: 192

Group type: COMPARATOR
Intervention: Face-forward positioning for at least 8 hours a day for 5 days post-surgery
Number of subjects: 192
Study: 25193578

Group type: EXPERIMENTAL
Intervention: Preoperative contrast-enhanced computerized tomography (CECT) in DTC patients
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Preoperative contrast-enhanced computerized tomography (CECT) in benign goiter patients
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Preoperative contrast-enhanced computerized tomography (CECT) in patients with non-thyroidal diseases
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control groups without CECT (DTC patients not undergoing CECT, benign goiter patients not undergoing CECT, and patients with non-thyroidal diseases not undergoing CECT)
Number of subjects: 128
Study: 23237211

Group type: EXPERIMENTAL
Intervention: Personalized one‐to‐one activities using Montessori principles
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non‐personalized activity (control)
Number of subjects: 44
Study: 21493423

Group type: EXPERIMENTAL
Intervention: KTP laser IT surgery
Number of subjects: 35

Group type: COMPARATOR
Intervention: INCS
Number of subjects: 35
Study: 19661078

Group type: EXPERIMENTAL
Intervention: CARET intervention (30 mg beta-carotene + 25,000 IU retinyl palmitate) with additional supplements
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Postintervention phase (CARET + other supplements)
Number of subjects: 890

Group type: COMPARATOR
Intervention: CARET intervention (30 mg beta-carotene + 25,000 IU retinyl palmitate)
Number of subjects: 890
Study: 16961710

Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium vaccae (1 mg)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium vaccae (0.1 mg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 15069048

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 5 ppm
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo (nitrogen gas)
Number of subjects: 385
Study: 11147718

Group type: EXPERIMENTAL
Intervention: buserelin MP 1.8 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: leuprolide 1.88 mg
Number of subjects: 67
Study: 9313717

Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomosis ring (BAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard suture technique
Number of subjects: 100
Study: 8324141

Group type: EXPERIMENTAL
Intervention: Accu-CulShure system
Number of subjects: 10

Group type: COMPARATOR
Intervention: B-D Port-a-Cul tube
Number of subjects: 10
Study: 3096429

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (five or six daily)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional twice daily insulin injections
Number of subjects: 45
Study: 29362371

Group type: EXPERIMENTAL
Intervention: CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX+/‐cetuximab
Number of subjects: 97
Study: 28077531

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.5 mmol kg‐1 for 1 h upon induction of anaesthesia followed by 0.15 mmol kg‐1 h‐1 for 23 h)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 162
Study: 24918556

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily for 8 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Lymecycline 300 mg daily for 8 weeks
Number of subjects: 170
Study: 22380717

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4-hydroxycyclophosphamide
Number of subjects: 23
Study: 20453567

Group type: EXPERIMENTAL
Intervention: Education program for asthma patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 79
Study: 18534327

Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (160 mg twice daily)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 15920008

Group type: EXPERIMENTAL
Intervention: Chemotherapy for acute lymphoblastic leukemia (ALL)
Number of subjects: 73
Study: 12545299

Group type: EXPERIMENTAL
Intervention: Tele‐ECG (12-lead ECG recorded by patients and transmitted via telephone)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Tele‐ECG
Number of subjects: 128
Study: 9893189

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone 100 microg administered twice daily for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8908414

Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE)
Number of subjects: 1947

Group type: EXPERIMENTAL
Intervention: Mattis Dementia Rating Scale (MDRS)
Number of subjects: 1947
Study: 1885267

Group type: EXPERIMENTAL
Intervention: 100ml orange juice with dissolved K‐ and Mg‐phosphates (K, 40mmol; Mg, 17.5mmol; HPO4, 35mmol)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Injection of ephedrine intravenously, 0.25mg/kg body weight
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100ml orange juice
Number of subjects: 36

Group type: COMPARATOR
Intervention: 100ml of water with electrolytes as in group I
Number of subjects: 36
Study: 6395614

Group type: EXPERIMENTAL
Intervention: Metronidazole (two-dose perioperative course, rectally administered)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: T-tube suction drainage
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Combination of metronidazole and T-tube suction drainage
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Suction drainage alone
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 198
Study: 31631008

Group type: EXPERIMENTAL
Intervention: Presence of silent ipsilateral brain ischaemia on magnetic resonance diffusion weighted imaging (MR-DWI)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intraplaque haemorrhage (IPH) presence
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression analysis correcting for age and type of index event
Number of subjects: 53
Study: 30126393

Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation (ORIF) for non-dislocated Lisfranc injuries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary Arthrodesis (PA) for dislocated Lisfranc injuries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cast-immobilization for non-dislocated Lisfranc injuries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Reduction and Internal Fixation (ORIF) for dislocated Lisfranc injuries
Number of subjects: 0
Study: 27112632

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream applied 3 times per week for 12 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 8
Study: 24981390

Group type: EXPERIMENTAL
Intervention: Presentation associated with an infectious diseases (ID) specialist intervention
Number of subjects: 249

Group type: COMPARATOR
Intervention: Simple presentation of audit feedback and guidelines
Number of subjects: 249
Study: 21678095

Group type: EXPERIMENTAL
Intervention: PRP group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study: 20626240

Group type: EXPERIMENTAL
Intervention: Metformin 2550 mg/day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Acarbose 300 mg/day
Number of subjects: 75
Study: 17716550

Group type: EXPERIMENTAL
Intervention: Oral glucose (75 g)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham isovolumetric unsweetened drink
Number of subjects: 19
Study: 15800139

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 5386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5386

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 5386
Study: 12576260

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day) + Conjugated estrogen cream (0.5 g)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day) + Nonhormonal moisturizer
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo + Conjugated estrogen cream (0.5 g)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo + Nonhormonal moisturizer
Number of subjects: 187
Study: 10385578

Group type: COMPARATOR
Intervention: Semantic decision task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phonological processing of words and pseudowords in a syllable-counting task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic processing
Number of subjects: 0
Study: 8723144

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 200 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 600 mg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1653795

Group type: EXPERIMENTAL
Intervention: Nifedipine (2 x 20 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hydergine (2 x 2 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination therapy (Nifedipine 20 mg/day and Hydergine 2 mg/day, twice daily each)
Number of subjects: 33
Study: 6805588

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg/day
Number of subjects: 9
Study: 31907776

Group type: EXPERIMENTAL
Intervention: CAV1 expression at primary site
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CAV1 expression at metastatic lymph nodes
Number of subjects: 80
Study: 31764099

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4572

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4572
Study: 28294173

Group type: EXPERIMENTAL
Intervention: UHT dairy milk (1.5 l for 21 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: PAST dairy milk (1.5 l for 21 days)
Number of subjects: 19
Study: 25750102

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention with participation of patients
Number of subjects: 946

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 946
Study: 22568828

Group type: EXPERIMENTAL
Intervention: FPSM/BDP (Fluticasone/Salmeterol + HFA-beclomethasone diproprionate 200 µg twice daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FPSM/PRED (Fluticasone/Salmeterol + Prednisolone 25 mg day(‐1) for 1 week)
Number of subjects: 15

Group type: COMPARATOR
Intervention: FPSM (Fluticasone/Salmeterol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FPSM/FP (Fluticasone/Salmeterol + Fluticasone 250 µg twice daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HFA-BDP (HFA-beclomethasone diproprionate 200 µg twice daily)
Number of subjects: 15
Study: 20733587

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 to 100 mg, adjustable to 25 mg)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 19330598

Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2) 0.5 mg
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Micronized estradiol (E2) 1.0 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 17100738

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo-PDT
Number of subjects: 45
Study: 15080865

Group type: EXPERIMENTAL
Intervention: MIDCAB
Number of subjects: 100

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 100
Study: 11590497

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imputation of missing data values
Number of subjects: 0
Study: 9284696

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy (400 mg/day for 2 weeks followed by 500 mg/day elemental calcium for 11 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Former etidronate group (1-year follow-up)
Number of subjects: 54
Study: 8335459

Group type: EXPERIMENTAL
Intervention: Natural interferon beta (5 million IU, 30-min i.v. infusion, three times weekly for 6 months)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (untreated symptomatic controls)
Number of subjects: 105
Study: 3594459

Group type: EXPERIMENTAL
Intervention: Oxiracetam (2 X 800 mg, orally, bid for 8 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (orally, bid for 8 weeks)
Number of subjects: 43
Study: 29720365

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 81
Study: 27217217

Group type: EXPERIMENTAL
Intervention: Monovalent oral rotavirus vaccine (RV1)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no RV1)
Number of subjects: 700
Study: 24252795

Group type: EXPERIMENTAL
Intervention: Large bowl (16 oz)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Small bowl (8 oz)
Number of subjects: 87
Study: 22236339

Group type: EXPERIMENTAL
Intervention: Acceptance-based coping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppression of emotions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 0
Study: 21302490

Group type: EXPERIMENTAL
Intervention: Conventional therapy + Smecta + Umbilical application of Lunxieting Paste (LXT) (Group C)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Conventional therapy + Smecta (Group B)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Conventional therapy only (Group A)
Number of subjects: 190
Study: 17967831

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg i.v. every 6 weeks)
Number of subjects: 69
Study: 16388068

Group type: EXPERIMENTAL
Intervention: Specialised care by the early onset team
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study: 12562457

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei supplementation (10^8 colony-forming units/mL L. casei, thrice daily during meals for 3 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (6 untreated H. pylori-positive subjects)
Number of subjects: 14
Study: 10801757

Group type: EXPERIMENTAL
Intervention: Intracoronary gamma-radiation therapy (15 Gy)
Number of subjects: 130
Study: 8633574

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (660 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1455853

Group type: EXPERIMENTAL
Intervention: Polnitrin (5 mg nitroglycerin buccal tablet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foreign analogue (5 mg nitroglycerin buccal tablet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (0.5 mg tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3968773

Group type: EXPERIMENTAL
Intervention: Adenosine monophosphate (AMP) treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study: 29605353

Group type: EXPERIMENTAL
Intervention: Primary rhinoseptoplasty (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No rhinoseptal correction (Group B)
Number of subjects: 40
Study: 27614124

Group type: EXPERIMENTAL
Intervention: Licorice in addition to the clarithromycin‐based triple regimen for two weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clarithromycin‐based triple regimen
Number of subjects: 120
Study: 25543323

Group type: EXPERIMENTAL
Intervention: Ligasure™
Number of subjects: 94

Group type: COMPARATOR
Intervention: Harmonic Ace®
Number of subjects: 94
Study: 24148131

Group type: EXPERIMENTAL
Intervention: ARV initiation after tuberculosis treatment onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18603575

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham-Inspiratory Muscle Training (sham-IMT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both IMT and sham-IMT
Number of subjects: 16
Study: 18958979

Group type: EXPERIMENTAL
Intervention: Participants who could leave feedback regarding the outcome of their interaction with their partner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who could not leave feedback regarding the outcome of their interaction with their partner
Number of subjects: 0
Study: 15860983

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of amlodipine besylate/benazepril HCl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril monotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 20
Study: 12770641

Group type: EXPERIMENTAL
Intervention: Progressive resistance-training program (24 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 45
Study: 10479469

Group type: EXPERIMENTAL
Intervention: Nicergoline (Cebran((R)), 2 cps day) for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 8736714

Group type: EXPERIMENTAL
Intervention: Heat‐washout method in thumb
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heat‐washout method in first toe
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heat‐washout method in ear lobe and nose
Number of subjects: 22
Study: 1880885

Group type: EXPERIMENTAL
Intervention: Higher-intensity group-based exercise training
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Higher-intensity home-based exercise training
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Lower-intensity home-based exercise training
Number of subjects: 357

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Home-based exercise training (both higher and lower intensity)
Number of subjects: 357
Study: 6213250

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fenoterol (2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and fenoterol (combination)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and fenoterol (both drugs)
Number of subjects: 8
Study: 30762760

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) tranexamic acid (TXA) 20 mg/kg before TKA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intra-articular (IA) tranexamic acid (TXA) 3.0 g after TKA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined IV (20 mg/kg) and IA (3.0 g) tranexamic acid (TXA)
Number of subjects: 150
Study: 27856940

Group type: EXPERIMENTAL
Intervention: Investigational cigarettes with 0.4 mg/g nicotine content
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Investigational cigarettes with 0.4 mg/g high tar nicotine content
Number of subjects: 839

Group type: COMPARATOR
Intervention: Control group (15.8 mg/g nicotine content)
Number of subjects: 839
Study: 27322475

Group type: EXPERIMENTAL
Intervention: CPAP with best supportive care (BSC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 55
Study: 25326074

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Both groups (mHealth and active control)
Number of subjects: 149
Study: 21658783

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZoMaxx)
Number of subjects: 1099

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (Taxus)
Number of subjects: 1099
Study: 19164458

Group type: EXPERIMENTAL
Intervention: FDG-PET after two cycles of chemotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FDG-PET metabolic response
Number of subjects: 51
Study: 17556905

Group type: EXPERIMENTAL
Intervention: Indoramin (25 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10